Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25044941 | 0.88 | TRPA1 (0.43) | FDPSALOX15CYP3A4CASP1CASP7 | |
| SCHEMBL10693501 | 0.81 | FDPS (0.38) | FDPSALOX15CYP3A4CASP1CASP7 | |
| SCHEMBL7065456 | 0.81 | EPHX1 (0.41) | FDPSALOX15CYP3A4CASP1CASP7 | |
| SCHEMBL7065461 | 0.81 | EPHX1 (0.41) | FDPSALOX15CYP3A4CASP1CASP7 | |
| SCHEMBL20749099 | 0.79 | TRPA1 (0.41) | FDPSALOX15CYP3A4CASP1CASP7 | |
| SCHEMBL3068875 | 0.77 | FDPS (0.41) | FDPSALOX15CYP3A4CASP1CASP7 | |
| SCHEMBL24383907 | 0.77 | — | — | |
| SCHEMBL4931748 | 0.74 | FDPS (0.39) | FDPSALOX15CYP3A4CASP1CASP7 | |
| SCHEMBL16197829 | 0.74 | FDPS (0.39) | FDPSALOX15CYP3A4CASP1CASP7 | |
| Isatoic Anhydride SCHEMBL29700086 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829597-B2 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1673078-B1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO INC (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1673078-A4 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060293380-A1 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | disclosed |
| EP-1673078-A2 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005032471-A2 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293380-A1 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | FDPS 978/4885ALOX15 1437/4885CYP3A4 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.